Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MDUFA V: Industry, FDA Tangle Over TAP Program, Agency Finances, Reinstatement Of Fifth-Year Offset Funds

Executive Summary

In newly published meeting minutes, industry and the US FDA continued to clash over a proposal to create a new pre-submission advisory program and what to do with carryover user-fee funds.

You may also be interested in...



FDA Begins ‘Soft’ TAP, Will Phase In Pilot Over Five Years

The US Food and Drug Administration has rolled out a program designed to speed up the development of innovative medical devices. The Total Product Lifecycle Advisory Program pilot was authorized under MDUFA V.

Pilot Program Aimed At Advancing Medical Device Development Set To Launch

The US Food and Drug Administration’s Total Product Lifecycle Advisory Program pilot, which was authorized under MDUFA V, will begin rolling out next year. The program is designed to speed up the development of innovative medical devices and make them more readily available to patients.

Pop The Champagne: Medtech Industry, FDA Reach MDUFA V User-Fee Deal

The deal includes a $110m Total Product Lifecycle Advisory Program pushed for by the US agency, but also credits unused funds past a certain threshold back to industry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel